Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3614-3623

  Kawashima, Hirotoshi ^a   Takatori, Hiroaki ^a   Suzuki, Kotaro ^a   Iwata, Arifumi ^a   Yokota, Masaya ^a   Suto, Akira ^a   Minamino, Tohru ^b   Hirose, Koichi ^a   Nakajima, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN ANTIBODY; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FOXP3 GENE; GASTRITIS; GENETIC TRANSCRIPTION; GLOMERULONEPHRITIS; HEPATITIS; IN VITRO STUDY; KNOCKOUT MOUSE; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY T LYMPHOCYTE; SIALOADENITIS; STOMACH PARIETAL CELL; THYROIDITIS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; INFLAMMATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885117482     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300509     Document Type: Article

References (45)

1. Vousden, K. H., and C. Prives. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431.
2. Green, D. R., and G. Kroemer. 2009. Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127-1130.
3. Herkel, J., N. Kam, N. Erez, A. Mimran, A. Heifetz, M. Eisenstein, V. Rotter, and I. R. Cohen. 2004. Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA. Eur. J. Immunol. 34:3623-3632.
4. Hara, T., F. Ogawa, E. Muroi, K. Komura, M. Takenaka, M. Hasegawa, M. Fujimoto, and S. Sato. 2008. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis. J. Rheumatol. 35:451-457.
5. Firestein, G. S., F. Echeverri, M. Yeo, N. J. Zvaifler, and D. R. Green. 1997. Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. USA 94:10895-10900.
6. Yamanishi, Y., D. L. Boyle, S. Rosengren, D. R. Green, N. J. Zvaifler, and G. S. Firestein. 2002. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl. Acad. Sci. USA 99:10025-10030.
7. Simelyte, E., S. Rosengren, D. L. Boyle, M. Corr, D. R. Green, and G. S. Firestein. 2005. Regulation of arthritis by p53:critical role of adaptive immunity. Arthritis Rheum. 52:1876-1884.
8. Leech, M., J. R. Xue, A. Dacumos, P. Hall, L. Santos, Y. Yang, M. Li, A. R. Kitching, and E. F. Morand. 2008. The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clin. Exp. Immunol. 152:345-353.
9. Okuda, Y., M. Okuda, and C. C. Bernard. 2003. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 135:29-37.
10. Zheng, S. J., S. E. Lamhamedi-Cherradi, P. Wang, L. Xu, and Y. H. Chen. 2005. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54:1423-1428.
11. Zhang, S., M. Zheng, R. Kibe, Y. Huang, L. Marrero, S. Warren, A. W. Zieske, T. Iwakuma, J. K. Kolls, and Y. Cui. 2011. Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 25:2387-2398.
12. + regulatory T cells. Nat. Immunol. 4:330-336.
13. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
14. + regulatory T cells in immune tolerance. Annu. Rev. Immunol. 30:733-758.
15. Jung, D. J., D. H. Jin, S. W. Hong, J. E. Kim, J. S. Shin, D. Kim, B. J. Cho, Y. I. Hwang, J. S. Kang, and W. J. Lee. 2010. Foxp3 expression in p53-dependent DNA damage responses. J. Biol. Chem. 285:7995-8002.
16. Singh, N., M. Yamamoto, M. Takami, Y. Seki, M. Takezaki, A. L. Mellor, and M. Iwashima. 2010. CD4+CD25+ regulatory T cells resist a novel form of CD28-and Fas-dependent p53-induced T cell apoptosis. J. Immunol. 184:94-104.
17. Lee, P. P., D. R. Fitzpatrick, C. Beard, H. K. Jessup, S. Lehar, K. W. Makar, M. Pérez-Melgosa, M. T. Sweetser, M. S. Schlissel, S. Nguyen, et al. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15:763-774.
18. Marino, S., M. Vooijs, H. van der Gulden, J. Jonkers, and A. Berns. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14:994-1004.
19. + regulatory T cells. Int. Immunol. 21:679-689.
20. + T cells. Immunity 1:553-562.
21. Hartmann, G., C. Bidlingmaier, B. Siegmund, S. Albrich, J. Schulze, K. Tschoep, A. Eigler, H. A. Lehr, and S. Endres. 2000. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 292:22-30.
22. Suzuki, K., S. H. Murphy, Y. Xia, M. Yokota, D. Nakagomi, F. Liu, I. M. Verma, and H. Nakajima. 2011. Tumor suppressor p53 functions as a negative regulator in IgE-mediated mast cell activation. PLoS ONE 6:e25412.
23. Kim, H. P., and W. J. Leonard. 2007. CREB/ATF-dependent T cell receptorinduced FoxP3 gene expression: a role for DNA methylation. J. Exp. Med. 204:1543-1551.
24. Tone, Y., K. Furuuchi, Y. Kojima, M. L. Tykocinski, M. I. Greene, and M. Tone. 2008. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9:194-202.
25. Hiramatsu, Y., A. Suto, D. Kashiwakuma, H. Kanari, S. Kagami, K. Ikeda, K. Hirose, N. Watanabe, M. J. Grusby, I. Iwamoto, and H. Nakajima. 2010. c-Maf activates the promoter and enhancer of the IL-21 gene, and TGF-b inhibits c-Maf-induced IL-21 production in CD4+ T cells. J. Leukoc. Biol. 87:703-712.
26. Ohkusu-Tsukada, K., T. Tsukada, and K. Isobe. 1999. Accelerated development and aging of the immune system in p53-deficient mice. J. Immunol. 163:1966-1972.
27. Kishimoto, T. 2005. Interleukin-6:from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23:1-21.
28. + T cells. J. Immunol. 173:6526-6531.
29. + T cell lineage differentiation. Immunity 30:646-655.
30. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212:8-27.
31. Villalba, M., S. Kasibhatla, L. Genestier, A. Mahboubi, D. R. Green, and A. Altman. 1999. Protein kinase cβ cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. J. Immunol. 163:5813-5819.
32. Smith-Garvin, J. E., G. A. Koretzky, and M. S. Jordan. 2009. T cell activation. Annu. Rev. Immunol. 27:591-619.
33. Liu, Y., and P. Zheng. 2007. FOXP3 and breast cancer: implications for therapy and diagnosis. Pharmacogenomics 8:1485-1487.
34. Hinz, S., L. Pagerols-Raluy, H. H. Oberg, O. Ammerpohl, S. Grüssel, B. Sipos, R. Grützmann, C. Pilarsky, H. Ungefroren, H. D. Saeger, et al. 2007. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res. 67:8344-8350.
35. Karanikas, V., M. Speletas, M. Zamanakou, F. Kalala, G. Loules, T. Kerenidi, A. K. Barda, K. I. Gourgoulianis, and A. E. Germenis. 2008. Foxp3 expression in human cancer cells. J. Transl. Med. 6:19.
36. Zuo, T., R. Liu, H. Zhang, X. Chang, Y. Liu, L. Wang, P. Zheng, and Y. Liu. 2007. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 117:3765-3773.
37. Zheng, Y., S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, and A. Y. Rudensky. 2010. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463:808-812.
38. Lee, Y. H., S. C. Bae, S. J. Choi, J. D. Ji, and G. G. Song. 2012. Associations between the p53 codon 72 polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Lupus 21:430-437.
39. Balomenos, D., J. Martín-Caballero, M. I. García, I. Prieto, J. M. Flores, M. Serrano, and C. Martínez-A. 2000. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat. Med. 6:171-176.
40. Santiago-Raber, M. L., B. R. Lawson, W. Dummer, M. Barnhouse, S. Koundouris, C. B. Wilson, D. H. Kono, and A. N. Theofilopoulos. 2001. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J. Immunol. 167:4067-4074.
41. Salvador, J. M., M. C. Hollander, A. T. Nguyen, J. B. Kopp, L. Barisoni, J. K. Moore, J. D. Ashwell, and A. J. Fornace, Jr. 2002. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16:499-508.
42. Burchill, M. A., J. Yang, C. Vogtenhuber, B. R. Blazar, and M. A. Farrar. 2007. IL-2 receptor b-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 178:280-290.
43. Ogura, H., M. Murakami, Y. Okuyama, M. Tsuruoka, C. Kitabayashi, M. Kanamoto, M. Nishihara, Y. Iwakura, and T. Hirano. 2008. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 29:628-636.
44. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 2011. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 186:3808-3821.
45. H2 inflammation. Nature 482:395-399.